Clinical Trials · NCT00039013
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 336
- Start date
- Mar 2002
- Locations
- 129 sites, United States
- Primary endpoint
- Change in HbA1c (glycosylated hemoglobin) from baseline to study termination (Week 30)